{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T10:52:28Z","timestamp":1753181548579},"reference-count":76,"publisher":"Asia Pacific Academy of Ophthalmology","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Asia Pac J Ophthalmol (Phila)"],"published-print":{"date-parts":[[2019]]},"DOI":"10.22608\/apo.2018108","type":"journal-article","created":{"date-parts":[[2018,4,18]],"date-time":"2018-04-18T04:38:16Z","timestamp":1524026296000},"source":"Crossref","is-referenced-by-count":2,"title":["Updates and Controversies in the Management of Acute Optic Neuritis"],"prefix":"10.22608","member":"9895","published-online":{"date-parts":[[2019]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1001\/archopht.126.7.994","article-title":"Treatment of acute optic neuritis: a summary of findings from the Optic Neuritis Treatment Trial","volume":"126","author":"RW","year":"2008","unstructured":"1. Beck RW, Gal RL. Treatment of acute optic neuritis: a summary of findings from the Optic Neuritis Treatment Trial. Arch Ophthalmol. 2008;126: 994\u2013995.","journal-title":"Arch Ophthalmol"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1001\/archopht.126.7.996","article-title":"The Optic Neuritis Treatment Trial","volume":"126","author":"Volpe","year":"2008","unstructured":"2. Volpe NJ. The Optic Neuritis Treatment Trial. Arch Ophthalmol. 2008;126: 996.","journal-title":"Arch Ophthalmol"},{"key":"ref2","first-page":"727","article-title":"Multiple sclerosis risk after optic neuritis: final Optic Neuritis Treatment Trial follow-up.","volume":"65","author":"Brodsky","year":"2008","unstructured":"3. Brodsky M, Nazarian S, Orengo-Nania S, et al. Multiple sclerosis risk after optic neuritis: final Optic Neuritis Treatment Trial follow-up. Arch Neurol. 2008;65:727\u2013732.","journal-title":"Arch Neurol","ISSN":"http:\/\/id.crossref.org\/issn\/0003-9942","issn-type":"print"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1016\/S0161-6420(95)30839-1","article-title":"What we have learned from the Optic Neuritis Treatment Trial","volume":"102","author":"RW","year":"1995","unstructured":"4. Beck RW, Trobe JD. What we have learned from the Optic Neuritis Treatment Trial. Ophthalmology. 1995;102:1504\u20131508.","journal-title":"Ophthalmology"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/j.ophtha.2007.08.004","article-title":"Visual function 15 years after optic neuritis. A final follow-up report from the Optic Neuritis Treatment Trial.","volume":"115","year":"2008","unstructured":"5. Optic Neuritis Study Group. Visual function 15 years after optic neuritis. A final follow-up report from the Optic Neuritis Treatment Trial. Ophthalmology. 2008;115:1079\u20121082.","journal-title":"Ophthalmology","ISSN":"http:\/\/id.crossref.org\/issn\/0161-6420","issn-type":"print"},{"key":"ref5","unstructured":"3. Clarivate Analytics. Web of Science cited reference search. http:\/\/apps.webofknowledge.com. Accessed March 11, 2018."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1056\/NEJM199202273260901","article-title":"The Optic Neuritis Study Group","volume":"326","author":"Beck","year":"1992","unstructured":"7. Beck RW, Cleary PA, Anderson MM Jr, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med. 1992;326:581\u2013588.","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1001\/archopht.1991.01080120057025","article-title":"The clinical profile of optic neuritis. Experience of the Optic Neuritis Treatment Trial.","volume":"109","year":"1991","unstructured":"8. Optic Neuritis Study Group. The clinical profile of optic neuritis. Experience of the Optic Neuritis Treatment Trial. Arch Ophthalmol. 1991;109: 1673\u20131678.","journal-title":"Arch Ophthalmol","ISSN":"http:\/\/id.crossref.org\/issn\/0003-9950","issn-type":"print"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1001\/archopht.1993.01090060061023","article-title":"One-year follow-up results","volume":"111","author":"RW","year":"1993","unstructured":"9. Beck RW, Cleary PA. Optic Neuritis Treatment Trial. One-year follow-up results. Arch Ophthalmol. 1993;111:773\u2013775.","journal-title":"Arch Ophthalmol"},{"issue":"February","key":"ref9","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1001\/jamaophthalmol.2017.6757","article-title":"Prevalence of myelin oligodendrocyte glycoprotein and aquaporin-4-IgG in patients in the Optic Neuritis Treatment Trial.","author":"Chen","year":"2018","unstructured":"10. Chen JJ, Tobin WO, Majed M, et al. Prevalence of myelin oligodendrocyte glycoprotein and aquaporin-4-IgG in patients in the Optic Neuritis Treatment Trial. JAMA Ophthalmol. February 22, 2018. [Epub ahead of print].","journal-title":"JAMA Ophthalmol","ISSN":"http:\/\/id.crossref.org\/issn\/2168-6165","issn-type":"print"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1111\/j.1600-0420.1997.tb00147.x","article-title":"A one-year follow-up","volume":"75","author":"Frederiksen","year":"1997","unstructured":"11. Frederiksen JL, Sorensen TL, Sellebjerg FT. Residual symptoms and signs after untreated acute optic neuritis. A one-year follow-up. Acta Ophthalmol Scand. 1997;75:544\u2013547.","journal-title":"Acta Ophthalmol Scand"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1136\/bjo.70.12.918","article-title":"Estimation of visual function after optic neuritis: a comparison of clinical tests","volume":"70","author":"Sanders","year":"1986","unstructured":"12. Sanders EA, Volkers AC, van der Poel JC, et al. Estimation of visual function after optic neuritis: a comparison of clinical tests. Br J Ophthalmol. 1986;70:918\u2013924.","journal-title":"Br J Ophthalmol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1212\/WNL.0b013e3181dbb664","article-title":"Evaluating loss of visual function in multiple sclerosis as measured by low-contrast letter acuity.","volume":"74","author":"Balcer","year":"2010","unstructured":"13. Balcer LJ, Frohman EM. Evaluating loss of visual function in multiple sclerosis as measured by low-contrast letter acuity. Neurology. 2010;74:S16\u2013S23.","journal-title":"Neurology","ISSN":"http:\/\/id.crossref.org\/issn\/0028-3878","issn-type":"print"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1097\/WNO.0000000000000421","article-title":"20\/40 or better visual acuity after optic neuritis: not as good as we once thought?","volume":"36","author":"Sabadia","year":"2016","unstructured":"14. Sabadia SB, Nolan RC, Galetta KM, et al. 20\/40 or better visual acuity after optic neuritis: not as good as we once thought? J Neuroophthalmol. 2016;36:369\u2013376.","journal-title":"J Neuroophthalmol","ISSN":"http:\/\/id.crossref.org\/issn\/1070-8022","issn-type":"print"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"e135","DOI":"10.1212\/NXI.0000000000000135","article-title":"Acute optic neuritis: unmet clinical needs and model for new therapies.","volume":"2","author":"Galetta","year":"2015","unstructured":"15. Galetta SL, Villoslada P, Levin N, et al. Acute optic neuritis: unmet clinical needs and model for new therapies. Neurol Neuroimmunol Neuroinflamm. 2015;2:e135.","journal-title":"Neurol Neuroimmunol Neuroinflamm","ISSN":"http:\/\/id.crossref.org\/issn\/2332-7812","issn-type":"print"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1001\/archopht.1995.01100020014004","article-title":"The Optic Neuritis Treatment Trial: three-year follow-up results [letter]","volume":"113","author":"Beck","year":"1995","unstructured":"16. Beck RW. The Optic Neuritis Treatment Trial: three-year follow-up results [letter]. Arch Ophthalmol. 1995;113:136\u2013137.","journal-title":"Arch Ophthalmol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1159\/000069408","article-title":"Perils and pitfalls in the interpretation of clinical trials: a reflection on the recent experience in multiple sclerosis","volume":"18","author":"Goodin","year":"1999","unstructured":"17. Goodin DS. Perils and pitfalls in the interpretation of clinical trials: a reflection on the recent experience in multiple sclerosis. Neuroepidemiology. 1999;18:53\u201363.","journal-title":"Neuroepidemiology"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1136\/jnnp-2014-308185","article-title":"Re-evaluating the treatment of acute optic neuritis","volume":"86","author":"Bennett","year":"2015","unstructured":"18. Bennett JL, Nickerson M, Costello F, et al. Re-evaluating the treatment of acute optic neuritis. J Neurol Neurosurg Psychiatry. 2015;86:799\u2013808.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref18","first-page":"CD001430","article-title":"Corticosteroids for treating optic neuritis.","volume":"80","author":"Gal","year":"2015","unstructured":"19. Gal RL, Vedula SS, Beck R. Corticosteroids for treating optic neuritis. Cochrane Database Syst Rev. 2015;80:CD001430.","journal-title":"Cochrane Database Syst Rev","ISSN":"http:\/\/id.crossref.org\/issn\/1469-493X","issn-type":"print"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jns.2008.08.039","article-title":"Management of optic neuritis and impact of clinical trials: an international survey","volume":"276","author":"Biousse","year":"2009","unstructured":"20. Biousse V, Calvetti O, Drews-Botsch CD, et al. Management of optic neuritis and impact of clinical trials: an international survey. J Neurol Sci. 2009;276:69\u201374.","journal-title":"J Neurol Sci"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1017\/S031716710000860X","article-title":"Management of optic neuritis in Canada: survey of ophthalmologists and neurologists","volume":"35","author":"Atkins","year":"2008","unstructured":"21. Atkins EJ, Drews-Botsch CD, Newman NJ, et al. Management of optic neuritis in Canada: survey of ophthalmologists and neurologists. Can J Neurol Sci. 2008;35:179\u2013184.","journal-title":"Can J Neurol Sci"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1016\/j.jocn.2008.01.014","article-title":"Management of acute optic neuritis: a survey of neurologists and ophthalmologists in Australia and New Zealand","volume":"15","author":"Lueck","year":"2008","unstructured":"22. Lueck CJ, Danesh-Meyer HV, Margrie FJ, et al. Management of acute optic neuritis: a survey of neurologists and ophthalmologists in Australia and New Zealand. J Clin Neurosci. 2008;15:1340\u20131345.","journal-title":"J Clin Neurosci"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.neurol.2007.12.005","article-title":"[Management of isolated optic neuritis in France: survey of neurologists and ophthalmologists]","volume":"164","author":"Calvetti","year":"2008","unstructured":"23. Calvetti O, Vignal-Clermont C, Drews-Botsch CD, et al. [Management of isolated optic neuritis in France: survey of neurologists and ophthalmologists]. Rev Neurol (Paris). 2008;164:233\u2013241.","journal-title":"Rev Neurol (Paris)"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/ana.23573","article-title":"A randomized, double-blind, phase 2 study of erythropoietin in optic neuritis","volume":"72","author":"S\u00fchs","year":"2012","unstructured":"24. S\u00fchs KW, Hein K, S\u00e4ttler MB, et al. A randomized, double-blind, phase 2 study of erythropoietin in optic neuritis. Ann Neurol. 2012;72:199\u2013210.","journal-title":"Ann Neurol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1093\/brain\/awq179","article-title":"Functional role of brain-derived neurotrophic factor in neuroprotective autoimmunity: therapeutic implications in a model of multiple sclerosis","volume":"133","author":"Linker","year":"2010","unstructured":"25. Linker RA, Lee DH, Demir S, et al. Functional role of brain-derived neurotrophic factor in neuroprotective autoimmunity: therapeutic implications in a model of multiple sclerosis. Brain. 2010;133:2248\u20132263.","journal-title":"Brain"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/S1474-4422(16)00004-1","article-title":"Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial","volume":"15","author":"Raftopoulos","year":"2016","unstructured":"26. Raftopoulos R, Hickman SJ, Toosy A, et al. Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2016;15:259\u2013269.","journal-title":"Lancet Neurol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1212\/01.WNL.0000152873.82631.B3","article-title":"A double-blind, randomized trial of IV immunoglobulin treatment in acute optic neuritis","volume":"64","author":"Roed","year":"2005","unstructured":"27. Roed HG, Langkilde A, Sellebjerge F, et al. A double-blind, randomized trial of IV immunoglobulin treatment in acute optic neuritis. Neurology. 2005;64:804\u2013810.","journal-title":"Neurology"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1212\/WNL.56.11.1514","article-title":"A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis","volume":"56","author":"Noseworthy","year":"2001","unstructured":"28. Noseworthy JH, O'Brien PC, Petterson TM, et al. A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis. Neurology. 2001;56:1514\u20131522.","journal-title":"Neurology"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S1474-4422(16)30377-5","article-title":"Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial","volume":"16","author":"Cadavid","year":"2017","unstructured":"29. Cadavid D, Balcer L, Galetta S, et al. Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2017;16:189\u2013199.","journal-title":"Lancet Neurol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1016\/S0140-6736(17)32346-2","article-title":"Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial","volume":"390","author":"Green","year":"2017","unstructured":"30. Green AJ, Gelfand JM, Cree BA, et al. Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial. Lancet. 2017;390:2481\u20132489.","journal-title":"Lancet"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1007\/s00415-016-8073-8","article-title":"Plasma exchange response in 34 patients with severe optic neuritis","volume":"263","author":"Deschamps","year":"2016","unstructured":"31. Deschamps R, Gueguen A, Parquet N, et al. Plasma exchange response in 34 patients with severe optic neuritis. J Neurol. 2016;263:883\u2013887.","journal-title":"J Neurol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1177\/1352458515581438","article-title":"Treatment of acute relapses in neuromyelitis optica: steroids alone versus steroids plus plasma exchange","volume":"22","author":"Abboud","year":"2016","unstructured":"32. Abboud H, Petrak A, Mealy M, et al. Treatment of acute relapses in neuromyelitis optica: steroids alone versus steroids plus plasma exchange. Mult Scler. 2016;22:185\u2013192.","journal-title":"Mult Scler"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1001\/archneurol.2011.34","article-title":"Beneficial plasma exchange response in central nervous system inflammatory demyelination","volume":"68","author":"Maga-a","year":"2011","unstructured":"33. Maga-a SM, Keegan BM, Weinshenker BG, et al. Beneficial plasma exchange response in central nervous system inflammatory demyelination. Arch Neurol. 2011;68:870\u2013878.","journal-title":"Arch Neurol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1002\/1531-8249(199912)46:6<878::AID-ANA10>3.0.CO;2-Q","article-title":"A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease","volume":"46","author":"Weinshenker","year":"1999","unstructured":"34. Weinshenker BG, O'Brien PC, Petterson TM, et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol. 1999;46:878\u2013886.","journal-title":"Ann Neurol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.mayocp.2016.12.014","article-title":"Neuromyelitis spectrum disorders","volume":"92","author":"BG","year":"2017","unstructured":"35. Weinshenker BG, Wingerchuk DM. Neuromyelitis spectrum disorders. Mayo Clin Proc. 2017;92:663\u2013679.","journal-title":"Mayo Clin Proc"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1212\/01.wnl.0000260695.72980.b7","article-title":"A population-based survey of multiple sclerosis in Shanghai, China","volume":"68","author":"Cheng","year":"2007","unstructured":"36. Cheng Q, Miao L, Zhang J, et al. A population-based survey of multiple sclerosis in Shanghai, China. Neurology. 2007;68:1495\u20131500.","journal-title":"Neurology"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1177\/1352458508098372","article-title":"Temporal changes and geographical differences in multiple sclerosis phenotypes in Japanese: nationwide survey results over 30 years","volume":"15","author":"Osoegawa","year":"2009","unstructured":"37. Osoegawa M, Kira J, Fukazawa T, et al. Temporal changes and geographical differences in multiple sclerosis phenotypes in Japanese: nationwide survey results over 30 years. Mult Scler. 2009;15:159\u2013173.","journal-title":"Mult Scler"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1159\/000229779","article-title":"Creutzfeldt-Jakob disease and multiple sclerosis","volume":"33","author":"Lai","year":"2009","unstructured":"38. Lai CH, Tseng HF. Population-based epidemiological study of neurological diseases in Taiwan: I. Creutzfeldt-Jakob disease and multiple sclerosis. Neuroepidemiology. 2009;33:247\u2013253.","journal-title":"Neuroepidemiology"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1097\/WCO.0000000000000328","article-title":"Demyelinating diseases in Asia","volume":"29","author":"Ochi","year":"2016","unstructured":"39. Ochi H, Fujihara K. Demyelinating diseases in Asia. Curr Opin Neurol. 2016;29:222\u2013228.","journal-title":"Curr Opin Neurol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1177\/1352458515572406","article-title":"Demographic and clinical features of neuromyelitis optica: a review","volume":"21","author":"Pandit","year":"2015","unstructured":"40. Pandit L, Asgari N, Apiwattanakul M, et al. Demographic and clinical features of neuromyelitis optica: a review. Mult Scler. 2015;21:845\u2013853.","journal-title":"Mult Scler"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1212\/WNL.0b013e31822c61b1","article-title":"AQP4 antibody-positive Thai cases: clinical features and diagnostic problems","volume":"77","author":"Siritho","year":"2011","unstructured":"41. Siritho S, Nakashima I, Takahashi T, et al. AQP4 antibody-positive Thai cases: clinical features and diagnostic problems. Neurology. 2011;77: 827\u2013834.","journal-title":"Neurology"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1002\/ana.24554","article-title":"Neuromyelitis optica: evaluation of 871 attacks and 1,153 treatment courses","volume":"79","author":"Kleiter","year":"2016","unstructured":"42. Kleiter I, Gahlen A, Borisow N, et al. Neuromyelitis optica: evaluation of 871 attacks and 1,153 treatment courses. Ann Neurol. 2016;79:206\u2013216.","journal-title":"Ann Neurol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12974-015-0256-1","article-title":"Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype","volume":"12","author":"Pr\u00f6bstel","year":"2015","unstructured":"43. Pr\u00f6bstel AK, Rudolf G, Dornmair K, et al. Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype. J Neuroinflammation. 2015;12:1\u20137.","journal-title":"J Neuroinflammation"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1097\/WCO.0000000000000446","article-title":"Myelin oligodendrocyte glycoprotein antibodies: how clinically useful are they?","volume":"30","author":"Reindl","year":"2017","unstructured":"44. Reindl M, Jarius S, Rostasy K, et al. Myelin oligodendrocyte glycoprotein antibodies: how clinically useful are they? Curr Opin Neurol. 2017;30: 295\u2013301.","journal-title":"Curr Opin Neurol","ISSN":"http:\/\/id.crossref.org\/issn\/1350-7540","issn-type":"print"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1136\/jnnp-2015-311743","article-title":"Antibodies to MOG and AQP4 in children with neuromyelitis optica and limited forms of the disease","volume":"87","author":"Lechner","year":"2016","unstructured":"45. Lechner C, Baumann M, Hennes EM, et al. Antibodies to MOG and AQP4 in children with neuromyelitis optica and limited forms of the disease. J Neurol Neurosurg Psychiatry. 2016;87:897\u2013905.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1001\/jamaneurol.2013.5857","article-title":"Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study","volume":"71","author":"Kitley","year":"2014","unstructured":"46. Kitley J, Waters P, Woodhall M, et al. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study. JAMA Neurol. 2014;71:276\u2013283.","journal-title":"JAMA Neurol"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1007\/s00415-016-8147-7","article-title":"Clinical spectrum associated with MOG autoimmunity in adults: significance of sharing rodent MOG epitopes","volume":"263","author":"Sep\u00falveda","year":"2016","unstructured":"47. Sep\u00falveda M, Armanque T, Martinez-Hernandez E, et al. Clinical spectrum associated with MOG autoimmunity in adults: significance of sharing rodent MOG epitopes. J Neurol. 2016;263:1349\u20131360.","journal-title":"J Neurol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12974-016-0718-0","article-title":"Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome","volume":"13","author":"Jarius","year":"2016","unstructured":"48. Jarius S, Ruprecht K, Kleiter I, et al; Neuromyelitis Optica Study Group. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation. 2016;13:1\u201345.","journal-title":"J Neuroinflammation"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12974-016-0720-6","article-title":"Part 4: Afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients","volume":"13","author":"Pache","year":"2016","unstructured":"49. Pache F, Zimmermann H, Mikolajczak J, et al; Neuromyelitis Optica Study Group. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: Afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients. J Neuroinflammation. 2016;13:1\u201310.","journal-title":"J Neuroinflammation"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s00415-016-8333-7","article-title":"Myelin-oligodendrocyte-glycoprotein (MOG) autoantibodies as potential markers of severe optic neuritis and subclinical retinal axonal degeneration","volume":"264","author":"Havla","year":"2017","unstructured":"50. Havla J, K\u00fcmpfel T, Schinner R, et al. Myelin-oligodendrocyte-glycoprotein (MOG) autoantibodies as potential markers of severe optic neuritis and subclinical retinal axonal degeneration. J Neurol. 2017;264:139\u2013151.","journal-title":"J Neurol"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jneuroim.2017.10.001","article-title":"Subclinical retinal atrophy in the unaffected fellow eyes of multiple sclerosis and neuromyelitis optica","volume":"313","author":"Akaishi","year":"2017","unstructured":"51. Akaishi T, Kaneko K, Himori N, et al. Subclinical retinal atrophy in the unaffected fellow eyes of multiple sclerosis and neuromyelitis optica. J Neuroimmunol. 2017;313:10\u201315.","journal-title":"J Neuroimmunol"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s10384-018-0561-1","article-title":"Diagnosis and treatment of anti-myelin oligodendrocyte glycoprotein antibody positive optic neuritis","volume":"62","author":"Kezuka","year":"2018","unstructured":"52. Kezuka T, Ishikawa H. Diagnosis and treatment of anti-myelin oligodendrocyte glycoprotein antibody positive optic neuritis. Jpn J Ophthalmol. 2018;62:101\u2013108.","journal-title":"Jpn J Ophthalmol"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.autrev.2015.12.004","article-title":"Anti-MOG antibody: the history, clinical phenotype, and pathogenicity of a serum biomarker for demyelination","volume":"15","author":"Ramanathan","year":"2016","unstructured":"53. Ramanathan S, Dale RC, Brilot F. Anti-MOG antibody: the history, clinical phenotype, and pathogenicity of a serum biomarker for demyelination. Autoimmun Rev. 2016;15:307\u2013324.","journal-title":"Autoimmun Rev"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1136\/adc.2009.175422","article-title":"Childhood optic neuritis clinical features and outcome","volume":"96","author":"Absoud","year":"2011","unstructured":"54. Absoud M, Cummins C, Desai N, et al. Childhood optic neuritis clinical features and outcome. Arch Dis Child. 2011;96:860\u2013862.","journal-title":"Arch Dis Child"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1212\/01.wnl.0000224757.69746.fb","article-title":"The clinical features, MRI findings, and outcome of optic neuritis in children","volume":"67","author":"Wilejto","year":"2006","unstructured":"55. Wilejto M, Shroff M, Buncic JR, et al. The clinical features, MRI findings, and outcome of optic neuritis in children. Neurology. 2006;67:258\u2013262.","journal-title":"Neurology"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1212\/WNL.0000000000001046","article-title":"Functional-structural correlations in the afferent visual pathway in pediatric demyelination","volume":"83","author":"Yeh","year":"2014","unstructured":"56. Yeh EA, Marrie RA, Reginald YA, et al. Functional-structural correlations in the afferent visual pathway in pediatric demyelination. Neurology. 2014; 83:2147\u20132152.","journal-title":"Neurology"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1023\/B:DOOP.0000005335.28820.05","article-title":"Optic neuritis in children--clinical and electrophysiological follow-up","volume":"107","author":"Tekavcic-Pompe","year":"2003","unstructured":"57. Tekavcic-Pompe M, Stirn-Kranjc B, Brecelj J. Optic neuritis in children--clinical and electrophysiological follow-up. Doc Ophthalmol. 2003;107:261\u2013270.","journal-title":"Doc Ophthalmol"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1212\/WNL.0000000000004312","article-title":"Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome","volume":"89","author":"Hennes","year":"2017","unstructured":"58. Hennes EM, Baumann M, Schanda K, et al. Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome. Neurology. 2017;89:900\u2013908.","journal-title":"Neurology"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1001\/jamaneurol.2017.4601","article-title":"Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"75","author":"Hacohen","year":"2018","unstructured":"59. Hacohen Y, Wong YY, Lechner C, et al. Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease. JAMA Neurol. 2018;75:478\u2012487.","journal-title":"JAMA Neurol"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1111\/j.1600-0404.1975.tb05774.x","article-title":"The epidemiology of optic neuritis in Finland","volume":"52","author":"Wikstr\u00f6m","year":"1975","unstructured":"60. Wikstr\u00f6m J. The epidemiology of optic neuritis in Finland. Acta Neurol Scand. 1975;52:196\u2013206.","journal-title":"Acta Neurol Scand"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1177\/1352458509359724","article-title":"Latitudinal variation in incidence and type of first central nervous system demyelinating events","volume":"16","author":"Taylor","year":"2010","unstructured":"61. Taylor BV, Lucas RM, Dear K, et al. Latitudinal variation in incidence and type of first central nervous system demyelinating events. Mult Scler. 2010; 16:398\u2013405.","journal-title":"Mult Scler"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1212\/WNL.0b013e31820af93d","article-title":"Sun exposure and vitamin D are independent risk factors for CNS demyelination","volume":"76","author":"Lucas","year":"2011","unstructured":"62. Lucas RM, Ponsonby AL, Dear K, et al. Sun exposure and vitamin D are independent risk factors for CNS demyelination. Neurology. 2011;76: 540\u2013548.","journal-title":"Neurology"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S1474-4422(13)70259-X","article-title":"Optic neuritis","volume":"13","author":"Toosy","year":"2014","unstructured":"63. Toosy AT, Mason DF, Miller DH. Optic neuritis. Lancet Neurol. 2014;13: 83\u201399.","journal-title":"Lancet Neurol"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1038\/eye.2011.81","article-title":"Optic neuritis","volume":"25","author":"Pau","year":"2011","unstructured":"64. Pau D, Al Zubidi N, Yalamanchili S, et al. Optic neuritis. Eye (Lond). 2011; 25:833\u2013842.","journal-title":"Eye (Lond)"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1136\/jnnp.2006.090910","article-title":"Is the frequency of abnormalities on magnetic resonance imaging in isolated optic neuritis related to the prevalence of multiple sclerosis? A global comparison","volume":"77","author":"Swanton","year":"2006","unstructured":"65. Swanton JK, Fernando K, Dalton CM, et al. Is the frequency of abnormalities on magnetic resonance imaging in isolated optic neuritis related to the prevalence of multiple sclerosis? A global comparison. J Neurol Neurosurg Psychiatry. 2006;77:1070\u20131072.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1212\/01.wnl.0000237641.33768.8d","article-title":"Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes","volume":"67","author":"Kappos","year":"2006","unstructured":"66. Kappos L, Polman CH, Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology. 2006;67:1242\u20131249.","journal-title":"Neurology"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/S0140-6736(09)61259-9","article-title":"Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial","volume":"374","author":"Comi","year":"2009","unstructured":"67. Comi G, Martinelli V, Rodegher M, et al; PreCISe Study Group. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet. 2009;374:1503\u20131511.","journal-title":"Lancet"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S1474-4422(11)70262-9","article-title":"Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial","volume":"11","author":"Comi","year":"2012","unstructured":"68. Comi G, De Stefano N, Freedman MS, et al. Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. Lancet Neurol. 2012;11:33\u201341.","journal-title":"Lancet Neurol"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/S1474-4422(14)70191-7","article-title":"Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"13","author":"Miller","year":"2014","unstructured":"69. Miller AE, Wolinsky JS, Kappos L, et al. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13:977\u2013986.","journal-title":"Lancet Neurol"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1056\/NEJM200009283431301","article-title":"CHAMPS Study Group","volume":"343","author":"Jacobs","year":"2000","unstructured":"70. Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med. 2000;343:898\u2013904.","journal-title":"N Engl J Med"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1016\/S0140-6736(00)04725-5","article-title":"Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study","volume":"357","author":"Comi","year":"2001","unstructured":"71. Comi G, Filippi M, Barkhof F, et al; Early Treatment of Multiple Sclerosis Study Group. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet. 2001;357:1576\u20131582.","journal-title":"Lancet"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"e0116511","DOI":"10.1371\/journal.pone.0116511","article-title":"The effect of disease modifying therapies on brain atrophy in patients with relapsing-remitting multiple sclerosis: a systematic review and meta-analysis.","volume":"10","author":"Tsivgoulis","year":"2015","unstructured":"72. Tsivgoulis G, Katsanos AH, Grigoriadis N, et al. The effect of disease modifying therapies on brain atrophy in patients with relapsing-remitting multiple sclerosis: a systematic review and meta-analysis. PLoS One. 2015; 10:e0116511.","journal-title":"PLoS One","ISSN":"http:\/\/id.crossref.org\/issn\/1932-6203","issn-type":"print"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1093\/brain\/awg081","article-title":"Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process","volume":"126","author":"Confavreux","year":"2003","unstructured":"73. Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain. 2003;126:770\u2013782.","journal-title":"Brain"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1136\/jnnp-2012-304333","article-title":"Onset of secondary progressive phase and long-term evolution of multiple sclerosis","volume":"85","author":"Scalfari","year":"2014","unstructured":"74. Scalfari A, Neuhaus A, Daumer M, et al. Onset of secondary progressive phase and long-term evolution of multiple sclerosis. J Neurol Neurosurg Psychiatry. 2014;85:67\u201375.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1093\/brain\/awm329","article-title":"Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis","volume":"131","author":"Fisniku","year":"2008","unstructured":"75. Fisniku LK, Brex PA, Altmann DR, et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain. 2008;131:808\u2013817.","journal-title":"Brain"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMoa011341","article-title":"A longitudinal study of abnormalities on MRI and disability from multiple sclerosis","volume":"346","author":"Brex","year":"2002","unstructured":"76. Brex PA, Ciccarelli O, O'Riordan JI, et al. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med. 2002;346:158\u2013164.","journal-title":"N Engl J Med"}],"container-title":["Asia-Pacific Journal of Ophthalmology"],"original-title":[],"deposited":{"date-parts":[[2019,6,28]],"date-time":"2019-06-28T20:08:45Z","timestamp":1561752525000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/apjoo\/Fulltext\/2018\/07000\/Updates_and_Controversies_in_the_Management_of.7.aspx"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":76,"URL":"https:\/\/doi.org\/10.22608\/apo.2018108","relation":{},"ISSN":["2162-0989","2162-0989"],"issn-type":[{"value":"2162-0989","type":"print"},{"value":"2162-0989","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019]]}}}